JP7817990B2 - 遺伝子異常に関係する稀なてんかん症候群に関連する発作の治療におけるカンナビジバリンの使用 - Google Patents

遺伝子異常に関係する稀なてんかん症候群に関連する発作の治療におけるカンナビジバリンの使用

Info

Publication number
JP7817990B2
JP7817990B2 JP2023515815A JP2023515815A JP7817990B2 JP 7817990 B2 JP7817990 B2 JP 7817990B2 JP 2023515815 A JP2023515815 A JP 2023515815A JP 2023515815 A JP2023515815 A JP 2023515815A JP 7817990 B2 JP7817990 B2 JP 7817990B2
Authority
JP
Japan
Prior art keywords
cbdv
seizures
pharmaceutical composition
motor
cannabinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023515815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540614A (ja
JP2023540614A5 (enExample
Inventor
ケヴィン・ジェームズ・クレイグ
ジョン・アンソニー・ローソン
Original Assignee
ジャズ・ファーマシューティカルズ・リサーチ・ユーケー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャズ・ファーマシューティカルズ・リサーチ・ユーケー・リミテッド filed Critical ジャズ・ファーマシューティカルズ・リサーチ・ユーケー・リミテッド
Publication of JP2023540614A publication Critical patent/JP2023540614A/ja
Publication of JP2023540614A5 publication Critical patent/JP2023540614A5/ja
Application granted granted Critical
Publication of JP7817990B2 publication Critical patent/JP7817990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2023515815A 2020-09-10 2021-09-08 遺伝子異常に関係する稀なてんかん症候群に関連する発作の治療におけるカンナビジバリンの使用 Active JP7817990B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2014250.1A GB202014250D0 (en) 2020-09-10 2020-09-10 Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2014250.1 2020-09-10
PCT/EP2021/074661 WO2022053486A1 (en) 2020-09-10 2021-09-08 Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

Publications (3)

Publication Number Publication Date
JP2023540614A JP2023540614A (ja) 2023-09-25
JP2023540614A5 JP2023540614A5 (enExample) 2024-08-22
JP7817990B2 true JP7817990B2 (ja) 2026-02-19

Family

ID=73149611

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515815A Active JP7817990B2 (ja) 2020-09-10 2021-09-08 遺伝子異常に関係する稀なてんかん症候群に関連する発作の治療におけるカンナビジバリンの使用

Country Status (10)

Country Link
US (1) US20230346809A1 (enExample)
EP (1) EP4210685B1 (enExample)
JP (1) JP7817990B2 (enExample)
KR (1) KR20230066417A (enExample)
CN (1) CN116234580A (enExample)
AU (1) AU2021341452A1 (enExample)
CA (1) CA3191266A1 (enExample)
GB (2) GB202014250D0 (enExample)
MX (1) MX2023002837A (enExample)
WO (1) WO2022053486A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
CA3264785A1 (en) 2022-08-12 2024-02-15 Jazz Pharmaceuticals Research Uk Limited ORAL SOLID DOSAGE FORMS CONTAINING CANNABINOIDS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523708A (ja) 2010-03-30 2013-06-17 ジーダブリュー・ファーマ・リミテッド てんかんの治療におけるフィトカンナビノイドカンナビジバリン（ｃｂｄｖ）の使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487183B (en) * 2011-01-04 2018-10-03 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2549278B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
GB2569961B (en) * 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2588458A (en) * 2019-10-25 2021-04-28 Gw Res Ltd Cannabidivarin preparations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523708A (ja) 2010-03-30 2013-06-17 ジーダブリュー・ファーマ・リミテッド てんかんの治療におけるフィトカンナビノイドカンナビジバリン（ｃｂｄｖ）の使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)，Clinicaltrials.gov ID NCT03202303，2020年08月21日
PUBLIC SUMMARY OF OPINION ON ORPHAN DESIGNATION: CANNABIDIVARIN FOR THE TREATMENT OF RETT SYNDROME，INTERNET CITATION，EUROPEAN MEDICINES AGENCY，2018年01月05日，PAGE(S):1-4，https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/17/1921-public-summary-opinion-orphan-designation-cannabidivarin-treatment-rett-syndrome_en.pdf
脳と発達，2014年，Vol.46，pp.117-120

Also Published As

Publication number Publication date
JP2023540614A (ja) 2023-09-25
GB202112440D0 (en) 2021-10-13
KR20230066417A (ko) 2023-05-15
MX2023002837A (es) 2023-03-17
AU2021341452A1 (en) 2023-03-23
CA3191266A1 (en) 2022-03-17
EP4210685B1 (en) 2025-11-26
GB2599492A (en) 2022-04-06
US20230346809A1 (en) 2023-11-02
GB202014250D0 (en) 2020-10-28
WO2022053486A1 (en) 2022-03-17
CN116234580A (zh) 2023-06-06
EP4210685A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
JP2023540614A (ja) 遺伝子異常に関係する稀なてんかん症候群に関連する発作の治療におけるカンナビジバリンの使用
JP7238037B2 (ja) てんかんの治療におけるカンナビジオールの使用
US12558362B2 (en) Use of cannabidiol in the treatment of seizures associated with rett syndrome
JP7650803B2 (ja) てんかんと関連する併存症の処置におけるカンナビノイドの使用
WO2022017942A1 (en) Use of cannabidiol in the treatment of seizures associated with mutations in the syngap1 gene
EP4181893A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
JP2022510292A (ja) てんかんの治療におけるカンナビノイドの使用
EP4181902A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
EP4181888A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017962A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597281A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
GB2601755A (en) Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes
MX2012011033A (es) Uso del fitocanabinoide canabidivarina (cbdv) para el tratamiento de epilepsia.
WO2022017936A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017957A1 (en) Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage
WO2022017944A1 (en) Use of cannabidiol in the treatment of seizures associated with bilateral cerebral dysgenesis
WO2022017915A1 (en) Cannabidiol for use in the treatment of seizures associated with brain damage
WO2022017930A1 (en) Use of cannabidiol in the treatment of seizures associated with jeavon's syndrome
GB2597296A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
GB2597305A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597283A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597278A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240809

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260206

R150 Certificate of patent or registration of utility model

Ref document number: 7817990

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150